Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Insulin therapy in the management of Type 2 diabetes is often postponed and/or not adequately intensified to maintain glycemic control because of the risk of weight gain and hypoglycemia. A fixed combination of the long-acting insulin degludec and liraglutide has recently been accepted by the EMA for the management of Type 2 diabetes. The incentive for this combination is to exploit the advantages of each of the drugs while counterbalancing the side effects. Insulin degludec effectively reduces fasting plasma glucose, but carries the risk of hypoglycemia and body weight gain. Liraglutide, on the other hand, exerts glycemic control with a minimal risk of hypoglycemia and, at the same time, reduces appetite and body weight.

TidsskriftExpert Review of Clinical Pharmacology
Udgave nummer3
Sider (fra-til)273-282
Antal sider10
StatusUdgivet - 1 maj 2015

Bibliografisk note

Publisher Copyright:
© Informa UK, Ltd.

ID: 305736595